Compare Dyne Therapeutics Inc. Common Stock (DYN) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs TeraWulf Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while TeraWulf Inc trades at $11.17 (market cap $6.59B). The key difference: TeraWulf Inc is far larger — about 2.3× Dyne Therapeutics Inc. Common Stock's market cap, and TeraWulf Inc is more actively traded (33,904,053 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and TeraWulf Inc for 18 Days on average.
| DYN | WULF | |
|---|---|---|
Market Cap | $2.86B | $6.59B |
Volume | 3,341,579 | 33,904,053 |
Sector | Health | Financials |
52-Week High | $26.78 | $28.98 |
52-Week Low | $14.60 | $10.99 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $2.18B | $9.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
WULF trades at $13.21, down 1.2% on the day, with a bearish technical signal from moving averages. The company reported a net loss of -$661.42M in 2025, with a negative net income margin of -1,179.94%, though it maintains a high gross profit margin of 69.26%. Recent news highlights its pivot to AI data centers, with shares experiencing volatility amid sector-wide momentum.
Analyst consensus is strongly bullish with a $34.92 price target, but high valuation ratios and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI infrastructure strategy amid substantial financial leverage and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
